Understanding Joe Biden’s Cancer Diagnoses: Prostate Cancer, Skin Cancer, and What Older Adults Need to Know

Public awareness surrounding former President Joe Biden's health has brought critical oncology topics back into the spotlight. Beyond political discussions, the medical realities of his dual diagnoses—an aggressive metastatic prostate cancer alongside localized non-melanoma skin cancer—offer valuable lessons for patients, families, and older adults navigating cancer screening and treatment.
Oncodaily
+ 1

Understanding the biology of these conditions, why screening guidelines change with age, and how modern therapies manage advanced disease can empower individuals to make informed decisions with their healthcare providers.

The Dual Diagnosis: Prostate Cancer and Non-Melanoma Skin Cancer

In May 2025, former President Joe Biden announced a diagnosis of Stage IV prostate cancer with bone metastases. Later, in September 2025, he underwent Mohs micrographic surgery to remove non-melanoma skin cancer (basal cell carcinoma) lesions from his head.
Oncodaily
+ 1

It is vital to understand that these two conditions are distinct:
Oncodaily

Primary Malignancy vs. Localized Lesions: Prostate cancer originates in the glandular tissue of the prostate. Skin cancers like basal cell carcinoma (BCC) arise in cutaneous cells, primarily due to cumulative ultraviolet (UV) radiation exposure over a lifetime.

Independent Pathologies: The occurrence of basal cell carcinoma does not mean the prostate cancer has spread to the skin. Instead, it reflects a common reality for older adults: managing multiple, unrelated oncological conditions concurrently as cellular repair mechanisms naturally slow down over time.
Oncodaily

Decoding Advanced Prostate Cancer: Gleason Scores and Metastasis

Medical reports revealed that Biden's prostate cancer was graded with a Gleason score of 9. To understand what this means, it helps to examine how oncologists evaluate prostate tumors:
Oncodaily

The Gleason Grading System: Pathologists examine biopsy tissue under a microscope and assign a pattern score from 1 to 5 based on how abnormal the cells look. The total Gleason score combines the two most dominant patterns. A score of 8 to 10 signifies high-grade, aggressive tumor cells that tend to grow and spread faster than lower-grade cells.
Michigan Medicine
+ 1

Bone Metastasis: Prostate cancer cells have a unique affinity for bone tissue. When cells break away from the primary tumor in the prostate, they often travel through the bloodstream or lymphatic system to settle in the axial skeleton (such as the spine, pelvis, or ribs).

Hormone Sensitivity: Despite being aggressive, initial testing confirmed the cancer was hormone-sensitive. According to the American Cancer Society, prostate cancer cells rely on male hormones (androgens, such as testosterone) to fuel their growth.
Boston University

Modern Management: Androgen Deprivation Therapy (ADT)

Because the cancer is hormone-sensitive, the foundational treatment relies on Androgen Deprivation Therapy (ADT). ADT uses targeted medications to lower androgen levels or block them from reaching cancer cells, effectively "starving" the tumor. While metastatic bone disease is generally considered incurable, ADT combined with modern secondary hormonal agents can suppress tumor growth and maintain quality of life for long periods.
Boston University
+ 2

Managing Non-Melanoma Skin Cancer with Mohs Surgery

While prostate cancer requires systemic treatments like hormonal therapy, localized skin cancers are treated topically or surgically. For basal cell carcinomas on sensitive or visible areas like the face or head, Mohs micrographic surgery is the clinical gold standard.
Oncodaily

What is Mohs Surgery?
Mohs surgery is a specialized surgical technique where the surgeon removes thin layers of cancer-containing skin one at a time. Each layer is immediately evaluated under a microscope in an on-site lab while the patient waits. The process is repeated until no microscopic signs of cancer remain.
Philippine News Agency

According to the Skin Cancer Foundation, Mohs surgery offers two key benefits:

Maximum Tissue Conservation: It preserves as much healthy surrounding tissue as possible, minimizing scarring.
Oncodaily

Highest Cure Rate: By verifying 100% of the surgical margins under a microscope during the procedure, it yields up to a 99% cure rate for primary basal cell carcinomas.

The Screening Dilemma: Why Guidelines Change with Age

A question frequently raised following Biden's diagnosis was why an aggressive cancer had spread before detection. The answer highlights a nuanced discussion in preventive medicine: age-based cancer screening guidelines.
Michigan Medicine

Standard screening for prostate cancer relies on the Prostate-Specific Antigen (PSA) blood test and digital rectal exams. However, clinical bodies like the U.S. Preventive Services Task Force generally advise stopping routine PSA screening after age 70 to 75.
Michigan Medicine
+ 1

Factor Screening Ages 55–69 Screening Age 70+
Primary Goal Early detection of localized, curable tumors. Balancing benefit against potential risks of overdiagnosis.
Risk of Overtreatment Low to moderate. High; many low-grade prostate cancers grow so slowly they never cause symptoms in a person's lifetime.
Guideline Recommendation Individual decision made with clinician. Routine screening generally discouraged unless life expectancy is long and symptoms are present.

When routine PSA testing is discontinued, aggressive prostate cancers (Gleason 8–10) can occasionally develop silently without early urinary symptoms. By the time symptoms like bone pain or urinary blockage appear, the disease may have already metastasized. This reflects the complex tradeoffs clinicians navigate when balancing preventive testing against invasive diagnostics in older adults.
Michigan Medicine
+ 1

Key Takeaways for Patients and Families

Discuss Personalized Screening: Screening decisions should be based on biological age, overall health, family history, and personal values rather than chronological age alone.
Michigan Medicine

Monitor Changes in Skin: Perform regular self-exams and schedule annual skin checks, especially if you have a history of sun exposure or previous skin lesions.
Oncodaily

Understand New Treatments: Advanced cancer treatments have improved significantly over the past decade. Even metastatic cancers can often be managed as chronic conditions with effective therapies.
Boston University

Report New Symptoms Promptly: Unexplained bone pain, unexpected weight loss, or changes in urinary habits warrant a discussion with a healthcare provider regardless of past screening history.

Sources

American Cancer Society
Boston University

Skin Cancer Foundation

U.S. Preventive Services Task Force

LuckeLadybug